Biomarker-enriched efficacy of cetuximab-based therapy: Squamous subset analysis from S0819, a phase III trial of chemotherapy with or without cetuximab in advanced NSCLC.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Fred R. Hirsch, Mary Weber Redman, Roy S. Herbst, Edward S. Kim, Thomas John Semrad, Lyudmila Bazhenova, Gregory A. Masters, Kurt R. Oettel, Perry Guaglianone, Christopher M. Reynolds, Anand B. Karnad, Susanne M. Arnold, Marileila Varella-Garcia, James Moon, Philip C. Mack, Charles David Blanke, Karen Kelly, David R. Gandara
Institutions: University of Colorado Cancer Center, Fred Hutch Cancer Center, Yale Cancer Center, Yale University, Carolinas Healthcare System, Levine Cancer Institute, University of California, Davis, University of California San Diego, Moores Cancer Center, Gundersen Lutheran Hospital, Cancer Care Specialists of Illinois, The University of Texas at San Antonio Health Science Center, University of Kentucky, Markey Cancer Center, University of Colorado Anschutz, UC Davis Comprehensive Cancer Center, Oregon Health & Science University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2890924342